Acta Oncologica最新文献_第9页

Infantile undifferentiated sarcomas: a diagnostic and therapeutic challenge - two case reports and literature review. 婴儿未分化肉瘤：诊断和治疗的挑战-两例报告和文献复习。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2025-02-10 DOI: 10.2340/1651-226X.2025.42162

Aleksandra Stanio, Jakub Czarny, Sandra Rutkowska, Katarzyna Adamczewska-Wawrzynowicz, Łukasz Młynarczyk, Agnieszka Stróżyk, Katarzyna Jończyk-Potoczna, Alicja Bartkowska-Śniatkowska, Jacek Wachowiak, Katarzyna Derwich, Olga Zając-Spychała

{"title":"Infantile undifferentiated sarcomas: a diagnostic and therapeutic challenge - two case reports and literature review.","authors":"Aleksandra Stanio, Jakub Czarny, Sandra Rutkowska, Katarzyna Adamczewska-Wawrzynowicz, Łukasz Młynarczyk, Agnieszka Stróżyk, Katarzyna Jończyk-Potoczna, Alicja Bartkowska-Śniatkowska, Jacek Wachowiak, Katarzyna Derwich, Olga Zając-Spychała","doi":"10.2340/1651-226X.2025.42162","DOIUrl":"10.2340/1651-226X.2025.42162","url":null,"abstract":"Background: Soft tissue undifferentiated sarcomas (STUS) are an ultra-rare and heterogenous group of mesenchymal neoplasms often lacking known genetic abnormalities with a marked vulnerability towards intensive therapy such as invasive surgery and high dose chemotherapy. Despite aggressive treatment, they are usually associated with dismal outcomes.Case presentation: Here we describe two cases of STUS in 3-week-old and 3-month-old infants localized on the neck and the trunk area.Discussion: In both cases, the malignancy had a fatal outcome due to the toxicity of intensive therapy in one case and the progression of the disease in the other. The purpose of this report is to discuss the clinical challenges of managing infancy-related STUS such as limited treatment options and poor prognosis.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"241-246"},"PeriodicalIF":2.7,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833329/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143389847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SleepNow - A combined cognitive behavioral therapy for insomnia and physical exercise intervention in men with metastatic prostate cancer: results from a feasibility randomized controlled trial. 一项针对转移性前列腺癌患者的失眠和体育锻炼的联合认知行为疗法：来自可行性随机对照试验的结果。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2025-02-09 DOI: 10.2340/1651-226X.2025.42246

Beverley Lim Høeg, Katrine Bjerre Løppenthin, Josée Savard, Christoffer Johansen, Jesper Frank Christensen, Mads Nordahl Svendsen, Niels Holländer, Pernille Envold Bidstrup

{"title":"SleepNow - A combined cognitive behavioral therapy for insomnia and physical exercise intervention in men with metastatic prostate cancer: results from a feasibility randomized controlled trial.","authors":"Beverley Lim Høeg, Katrine Bjerre Løppenthin, Josée Savard, Christoffer Johansen, Jesper Frank Christensen, Mads Nordahl Svendsen, Niels Holländer, Pernille Envold Bidstrup","doi":"10.2340/1651-226X.2025.42246","DOIUrl":"10.2340/1651-226X.2025.42246","url":null,"abstract":"focused on patients living with metastatic cancer. We examined the feasibility of the SleepNow intervention combining cognitive behavioral therapy for insomnia (CBT-I) with physical exercise in men with metastatic prostate cancer (mPCa).Patients/material and methods: We conducted a feasibility randomized trial in patients under treatment for castration resistant mPCa with insomnia (Insomnia Severity Index [ISI] score ≥ 8). Patients were randomized 1:1 to either SleepNow or usual care. SleepNow is a manualized 12-week program consisting of bi-weekly sessions of physical exercise and four nurse-led sessions of CBT-I. Patients in usual care received no insomnia treatment. We assessed feasibility and measured objective and patient-reported outcomes at baseline and 3-months follow-up. Changes in both groups were compared using the Wilcoxon test.Results: We randomized 12 patients (5 intervention and 7 control; age range = 59-81 years, mean Gleason score = 7.75, mean time since diagnosis ≈ 7 years). Intervention patients reported high satisfaction, all attended at least three CBT-I sessions (75%) and four completed at least 20 of the 24 training sessions. The intervention group showed improvements in insomnia, sleep quality, fatigue, anxiety, depression and health-related quality-of-life but between-group differences were not statistically significant.Interpretation: The SleepNow intervention is the first to combine nurse-delivered CBT-I and physical exercise and was acceptable and potentially efficacious. Our results are important for targeting sleep interventions to the growing population of patients living long term with metastatic cancer.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"222-228"},"PeriodicalIF":2.7,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143381509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sexual distress among men with cancer - a cross-sectional study. 男性癌症患者的性困扰——一项横断面研究。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2025-02-09 DOI: 10.2340/1651-226X.2025.42525

Jonas Nahavandipour, Christoffer Johansen, Annamaria Giraldi, Bolette Skjøft Rafn, Annika Von Heymann

{"title":"Sexual distress among men with cancer - a cross-sectional study.","authors":"Jonas Nahavandipour, Christoffer Johansen, Annamaria Giraldi, Bolette Skjøft Rafn, Annika Von Heymann","doi":"10.2340/1651-226X.2025.42525","DOIUrl":"10.2340/1651-226X.2025.42525","url":null,"abstract":"Background and purpose: Many men with cancer experience that changes created by cancer and its treatment may impair sexual function. However, many studies investigating sexual impairments fail to consider whether such impairments are perceived as distressing, i.e. create sexual distress. We investigated the prevalence of sexual distress, overlap with sexual impairment, and sociodemographic and clinical characteristics and other symptoms associated with sexual distress in a heterogeneous male cancer population.Patients and methods: Across cancer diagnoses, 2792 men in treatment or follow up at the Department of Oncology, Rigshospitalet, were invited. The Sexual Complaint Screener (SCS) assessed sexual impairments and sexual distress. Regression analyses estimated the association of sexual distress with sociodemographic and tumor-related factors, other symptoms (pain, depression, fatigue, insomnia, fear of recurrence), and health-related quality of life. The number of patients who received help for or were interested in a consultation for sexual problems was calculated.Results: Six hundred and ninety-six patients, most frequently diagnosed with testicular (26%) or multiple (16%) cancers, completed the SCS. Forty-one per cent experienced sexual distress, 60% sexual impairment, and 34% overlapping sexual distress and impairment. Sexual distress was significantly associated with clinically relevant insomnia (OR:2.15; 95% CI:1.5-3.1) and pain (OR:1.90; 95% CI:1.3-2.9). Two thirds of all patients wished for help, but only one third of these were receiving help.Interpretation: Sexual distress was widespread in men across different cancer diagnoses and sometimes presented without impairment, demonstrating that assessment of sexual problems must include the personal experience of distress and extend to men across cancer diagnoses.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"214-221"},"PeriodicalIF":2.7,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833328/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143381500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Determining the effect of frailty on survival in advanced ovarian cancer: study protocol for a prospective multicentre national cohort study (FOLERO). 确定衰弱对晚期卵巢癌患者生存的影响：一项前瞻性多中心国家队列研究（FOLERO）的研究方案。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2025-02-05 DOI: 10.2340/1651-226X.2025.42292

Daniel Hunde, Niklas Ekerstad, Mihaela Asp, Päivi Kannisto, Madelene Wedin, Charlotte Palmqvist, Pernilla Dahm-Kähler, Yvonne Brandberg, Mirna Abraham-Nordling, Kristina Åhlund, Vilhelm Mörlin, Nina Groes-Kofoed, Sahar Salehi

{"title":"Determining the effect of frailty on survival in advanced ovarian cancer: study protocol for a prospective multicentre national cohort study (FOLERO).","authors":"Daniel Hunde, Niklas Ekerstad, Mihaela Asp, Päivi Kannisto, Madelene Wedin, Charlotte Palmqvist, Pernilla Dahm-Kähler, Yvonne Brandberg, Mirna Abraham-Nordling, Kristina Åhlund, Vilhelm Mörlin, Nina Groes-Kofoed, Sahar Salehi","doi":"10.2340/1651-226X.2025.42292","DOIUrl":"10.2340/1651-226X.2025.42292","url":null,"abstract":"Background and purpose: There is an urgent need to improve patient-selection to surgical treatment in advanced ovarian cancer as our results showed that cytoreductive surgery was without effect or even detrimental in a yet unknown subgroup of women. With an ageing population, 30% of women with advanced ovarian cancer in Sweden are >75 years. Nevertheless, there are no recommendations on patient-selection, albeit treating an unselected population in a public and centralized health care setting. Little attention has been placed on frailty assessments in oncology, despite their potential to stratify the risk of adverse outcome and mortality. Consequently, we hypothesize that frailty is a predictor of poor survival.Patients and methods: In this Swedish multi-centre prospective cohort study, where the exposure is frailty, consecutive women with advanced ovarian cancer scheduled for surgery with curative intent are eligible for inclusion. Three different frailty instruments are evaluated preoperatively, blinded to the caregiver. The primary outcome is 2-year overall survival. With a fixed sample size of 450 patients, a two-sided α of 0.05 and β of 0.20, the study is powered to detect a difference in 2-year survival of 12.5% by frailty, assuming a 20% prevalence of frailty. The result of the study will have a direct impact on clinical management and patient-selection as the results are expected to have a high external validity. Total study-time is 5 years, with 3 years of accrual. All participating centres started accrual by September 2024. Presentation of data on primary outcome is expected 2029.Study registration: ClinicalTrials.gov NCT06298877.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"208-213"},"PeriodicalIF":2.7,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11816292/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143187907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiac CT reveals high prevalence of coronary artery disease in esophageal cancer eligible for radiotherapy. 心脏CT显示食管癌患者冠状动脉病变高发，适合放射治疗。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2025-02-03 DOI: 10.2340/1651-226X.2025.42563

Akinori Takada, Satoshi Nakamura, Yutaka Toyomasu, Takamitsu Mase, Tomoko Kawamura, Suguru Araki, Yoshitaka Suzuki, Masaki Ohi, Hajime Sakuma, Yoshihito Nomoto, Kakuya Kitagawa

{"title":"Cardiac CT reveals high prevalence of coronary artery disease in esophageal cancer eligible for radiotherapy.","authors":"Akinori Takada, Satoshi Nakamura, Yutaka Toyomasu, Takamitsu Mase, Tomoko Kawamura, Suguru Araki, Yoshitaka Suzuki, Masaki Ohi, Hajime Sakuma, Yoshihito Nomoto, Kakuya Kitagawa","doi":"10.2340/1651-226X.2025.42563","DOIUrl":"10.2340/1651-226X.2025.42563","url":null,"abstract":"Background: Assessment of cardiac disease before cancer therapy is crucial, as advancements in cancer treatment have led to prolonged survival and an increase in cardiovascular complications. Specifically, esophageal cancer and heart disease share common risk factors, such as smoking and obesity. Radiation therapy (RT) for esophageal cancer is associated with elevated cardiac radiation exposure. This study aimed to assess the prevalence of coronary artery disease (CAD) in patients with esophageal cancer who were eligible for RT.Methods: We examined the prevalence of coronary artery stenosis, abnormal myocardial perfusion, and late enhancement using pre-RT cardiac computed tomography (CT) data of 41 patients with thoracic esophageal cancer who were referred for RT between January 2017 and June 2023 and had no history of ischemic heart disease.Results: The median age of the 41 patients was 71 years, with 40 patients being male. Cardiac CT identified significant coronary stenosis (≥50% luminal narrowing) in 18 patients (44%), among whom 9 (50%) had severe stenosis, multivessel disease, or myocardial ischemia. Significant stenosis was most frequently observed in the left anterior descending artery (16/18). Late enhancement, indicating myocardial infarction, was observed in seven patients (17%).Interpretation: Patients with esophageal cancer without a history of ischemic heart disease had a high prevalence (44%) of CAD, with half of them having severe stenosis, multivessel disease, or myocardial ischemia. Given the high prevalence of coronary stenosis, pre-treatment cardiac evaluation is crucial for patients with esophageal cancer. Incorporating cardiac CT findings into radiotherapy planning is recommended to optimize patient care.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"200-207"},"PeriodicalIF":2.7,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143077902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relapse detection in the Danish surveillance program of patients with clinical stage I seminoma: a nationwide study. 丹麦临床I期精原细胞瘤患者监测项目中的复发检测：一项全国性研究。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2025-01-31 DOI: 10.2340/1651-226X.2025.42281

Niklas B Lindahl, Jakob Lauritsen, Thomas Wagner, Gedske Daugaard, Mikkel Bandak

{"title":"Relapse detection in the Danish surveillance program of patients with clinical stage I seminoma: a nationwide study.","authors":"Niklas B Lindahl, Jakob Lauritsen, Thomas Wagner, Gedske Daugaard, Mikkel Bandak","doi":"10.2340/1651-226X.2025.42281","DOIUrl":"10.2340/1651-226X.2025.42281","url":null,"abstract":"Background and purpose: Active surveillance is a recommended management strategy for patients with clinical stage I (CSI) seminoma. This study aims to identify patterns of relapse detection methods in an unselected population-based cohort of CSI patients and provide evidence for a risk-adapted follow-up program.Patients/materials and methods: A total of 924 patients with CSI seminoma were identified in the prospective Danish Testicular Cancer database. Retrospectively collected clinical data were used for descriptive analyses of patterns in detection methods. Additionally, we explored a risk-adapted surveillance approach based on recently identified risk factors for relapse, classifying patients into low- and non-low-risk groups.Results: At 60 months, the 5-year cumulative relapse risk was 16%, with 146 relapses during surveillance. Relapses were detected by imaging alone in 71% of cases, imaging combined with elevated serum tumor markers (STMs) in 18%, isolated elevation of STMs in 8%, and by self-referral due to symptoms in 3%. No relapses were detected by abnormal findings at a physical examination. In total, 134 (92%) relapses were localized to retroperitoneal lymph nodes, primarily without additional spread. The 5-year relapse risk in patients with low risk of relapse was 9% compared to 28% in patients in the non-low-risk group.Interpretation: This study highlights that the surveillance program can detect relapses at an early stage. Reduction of visits and omission of routine physical examinations can safely be considered for patients with a low risk of relapse, while further research is needed to optimize follow-up and treatment for patients at higher risk of relapse.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"191-199"},"PeriodicalIF":2.7,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143063165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lynch syndrome screening in colorectal and endometrial cancers in Iceland. 冰岛结直肠癌和子宫内膜癌林奇综合征筛查。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2025-01-31 DOI: 10.2340/1651-226X.2025.41957

Katla R Kluvers, Thordur Tryggvason, Vigdis Stefansdottir, Jon G Jonasson, Petur Snaebjornsson, Sigurdis Haraldsdottir

{"title":"Lynch syndrome screening in colorectal and endometrial cancers in Iceland.","authors":"Katla R Kluvers, Thordur Tryggvason, Vigdis Stefansdottir, Jon G Jonasson, Petur Snaebjornsson, Sigurdis Haraldsdottir","doi":"10.2340/1651-226X.2025.41957","DOIUrl":"10.2340/1651-226X.2025.41957","url":null,"abstract":"Background and purpose: Screening for Lynch syndrome (LS) with mismatch repair (MMR) protein immunohistochemistry (IHC) in all patients with newly diagnosed colorectal (CRC) and endometrial cancer (EC) was implemented in Iceland in 2017. The aim of the study is to assess the accuracy of screening in 2020-2022 and compare it to 2017-2019 when screening was initiated.Patients/materials and methods: All patients diagnosed with CRC and EC according to the Icelandic Cancer Registry in 2020-2022 were included. Screening results were crossmatched with a genotyping database from deCODE to calculate sensitivity and specificity for LS detection. Results: In 2020-2022, 429 of 522 (82%) diagnosed CRCs were stained and 90 of 106 (85%) ECs, compared to 74% of CRCs and 82% of ECs in 2017-2019. The screening protocol was followed in 90% of cases for CRCs and 95% of cases for ECs compared to 89% and 68% during 2017-2019. The sensitivity of IHC as a screening method for LS was 70% and specificity 88% with a positive and negative predictive value of 8.4% and 99.4%, respectively.Interpretation: Three LS cases were missed with MMR IHC (1 MSH6 and 2 PMS2 carriers), it is possible these patients had sporadic cancers unrelated to their LS carrier status. MSH6 and PMS2 deficiency strongly predicts LS in Iceland.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"188-190"},"PeriodicalIF":2.7,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811529/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143063133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world treatment patterns and survival outcomes in men with metastatic castration-resistant prostate cancer in Finland: a national, population-based cohort study. 芬兰男性转移性去势抵抗性前列腺癌患者的现实世界治疗模式和生存结果：一项全国性、基于人群的队列研究

IF 2.7 3区医学

Acta Oncologica Pub Date : 2025-01-29 DOI: 10.2340/1651-226X.2025.42173

Antti Rannikko, Olivia Hölsä, Trude Ågesen, Mattias Ekman, Riikka Mattila

{"title":"Real-world treatment patterns and survival outcomes in men with metastatic castration-resistant prostate cancer in Finland: a national, population-based cohort study.","authors":"Antti Rannikko, Olivia Hölsä, Trude Ågesen, Mattias Ekman, Riikka Mattila","doi":"10.2340/1651-226X.2025.42173","DOIUrl":"10.2340/1651-226X.2025.42173","url":null,"abstract":"Background: Metastatic castration-resistant prostate cancer (mCRPC) treatment is advancing yet Nordic, real-world evidence for its use is scarce. In this population-based cohort study, we describe characteristics of patients with mCRPC, and their treatment patterns and survival outcomes in Finland.Methods: Incident patients with mCRPC diagnosed during 2013-2021 were identified from data lakes in two large and representative, Finnish hospital districts, and linked to data on drug purchases and causes of death from national registries.Results: Of a total of 31,307 patients with prostate cancer, 2,475 progressed to mCRPC during 2013-2021. Those who received no life-prolonging treatment(s) (28% overall) were older with more comorbidities than treated patients. After 2018, the proportion of patients who received life-prolonging treatments increased from 61% to 80%. Of those who received treatment before androgen receptor pathway inhibitors (ARPIs) were reimbursed as first-line (1L) treatment for mCRPC in Finland, 68% received docetaxel, 19% abiraterone and 12% enzalutamide 1L; post-reimbursement, 4% received docetaxel, 24% abiraterone and 71% enzalutamide 1L. Median overall survival for treated patients with mCRPC was 28.3 (95% CI: 26.3-30.4) and 38.5 (95% CI: 32.7-42.1) months pre- and post-reimbursement of 1L-ARPIs, respectively.Interpretation: The ARPI reimbursement status changes significantly influenced treatment patterns for mCRPC in Finland, favouring enzalutamide over docetaxel. This expanded the pool of men eligible for 1L treatment and improved overall survival by a median of 10 months. These findings highlight the importance of health policy decisions in shaping treatment strategies and patient outcomes in prostate cancer.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"173-178"},"PeriodicalIF":2.7,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11808809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143063149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Socioeconomic characteristics and relapse-free and overall survival from childhood cancer - a nationwide study based on data from the Danish Childhood Cancer Registry. 儿童癌症的社会经济特征和无复发和总生存率——一项基于丹麦儿童癌症登记处数据的全国性研究。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2025-01-29 DOI: 10.2340/1651-226X.2025.42131

Fie Stegenborg, Mathilde Bek, Charlotte Nilsson, Line H Pedersen, Thomas Scheike, Lisa Hjalgrim, Friederike Erdmann, Kjeld Schmiegelow, Pernille Bidstrup, Line Kenborg, Jeanette Winther, Hanne Larsen, Susanne Dalton

{"title":"Socioeconomic characteristics and relapse-free and overall survival from childhood cancer - a nationwide study based on data from the Danish Childhood Cancer Registry.","authors":"Fie Stegenborg, Mathilde Bek, Charlotte Nilsson, Line H Pedersen, Thomas Scheike, Lisa Hjalgrim, Friederike Erdmann, Kjeld Schmiegelow, Pernille Bidstrup, Line Kenborg, Jeanette Winther, Hanne Larsen, Susanne Dalton","doi":"10.2340/1651-226X.2025.42131","DOIUrl":"10.2340/1651-226X.2025.42131","url":null,"abstract":"Background and purpose: Over the past decades, childhood cancer survival has increased substantially in Europe, including Denmark. However, families with fewer social resources may have benefitted less from these improvements. In this nationwide register-based study, we assessed associations between parental socioeconomic position (SEP) and 5-year relapse-free survival (RFS) and overall survival (OS) in childhood cancer patients.Material and methods: All children aged <16 years diagnosed with cancer in Denmark between 1998 and 2017 were identified in the Danish Childhood Cancer Registry (N = 3245). Parents, with whom the children resided, were identified, and data on the parents' education, cohabitation status, affiliation to work market, country of origin, and vital status of the children were obtained through individual-level linkage across Danish nationwide registries. Cox proportional hazards models were used to estimate the association between SEP indicators and 5-year RFS and OS.Results and interpretation: Tendencies towards lower 5-year RFS and OS were observed among children whose parents were unemployed/not in workforce (RFS: HR [hazard ratio] = 1.14, 95% CI [confidence interval]: 0.90-1.45, OS: HR = 1.28, 95% CI: 0.95-1.71) or from non-Western countries (RFS: HR = 1.21 95% CI: 0.96-1.52, OS: HR = 1.44, 95% CI: 1.09-1.90). Results by diagnostic groups revealed particularly low OS for children with non-central nervous system tumors whose parents were from non-Western countries (HR = 1.92, 95% CI: 1.24-2.97). Targeted strategies are needed to promote social equity and ensure optimal diagnosis, care, and management of childhood cancer across social groups.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"179-187"},"PeriodicalIF":2.7,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11808813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143063166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pembrolizumab as first-line treatment for recurrent and metastatic head and neck cancer - real-world single-centre data. 派姆单抗作为复发性和转移性头颈癌的一线治疗——真实世界单中心数据

IF 2.7 3区医学

Acta Oncologica Pub Date : 2025-01-28 DOI: 10.2340/1651-226X.2025.42128

Bogdana Patachi, Kristian H Jensen, Anita Gothelf, Mogens Bernsdorf, Jeppe Friborg, Claus A Kristensen

{"title":"Pembrolizumab as first-line treatment for recurrent and metastatic head and neck cancer - real-world single-centre data.","authors":"Bogdana Patachi, Kristian H Jensen, Anita Gothelf, Mogens Bernsdorf, Jeppe Friborg, Claus A Kristensen","doi":"10.2340/1651-226X.2025.42128","DOIUrl":"10.2340/1651-226X.2025.42128","url":null,"abstract":"Background and purpose: The randomised clinical trial KEYNOTE-048 has demonstrated a significant increase in survival for patients with head and neck cancer treated with pembrolizumab with or without chemotherapy. The purpose of the present retrospective study was to investigate whether survival in a group of consecutive patients treated at our department was comparable to the results from KEYNOTE-048.Patients/material and methods: Seventy-six patients initiated treatment with pembrolizumab ± platinum/5-FU between July 2020 and May 2022. Baseline characteristics were collected, response rates and survival times were calculated and compared to those published from KEYNOTE-048.Results and interpretation: Fifty-one percent of patients had locoregional recurrence and 47% had distant metastases. Median progression-free survival was 5.5 months, and median overall survival (OS) was 12.3 months in the total cohort. OS was significantly higher for patients with combined positive score (CPS) ≥20 (14.6 months) than for patients with CPS 1-19 (7.3 months) (p = 0.04). There was no significant difference in survival times between patients ± 65 years of age or between patients with locoregional disease versus distant metastases. In conclusion, the results from KEYNOTE-048 were corroborated in a consecutive cohort of patients treated at Rigshospitalet, Copenhagen, Denmark.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"143-146"},"PeriodicalIF":2.7,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11794996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143057646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0